{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-023798","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2024-06-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.003343+00:00","generated_at":"2026-06-01T04:16:08.393758+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lixte enters Phase 1b/2 trial of LB-100 + atezolizumab for metastatic colorectal cancer with NKI","bullets":["Trial combines Lixte's PP2A inhibitor LB-100 with Roche's atezolizumab; company provides LB-100 only.","Roche provides atezolizumab and financial support; Lixte has no obligation to reimburse trial costs.","Phase 1b/2 study led by Dr. Neeltje Steeghs at NKI in Amsterdam; opens by June 30, 2024.","Patient accrual up to 24 months; maximum 37 metastatic microsatellite stable colorectal cancer patients.","Dose escalation to determine RP2D; expansion phase evaluates safety, tolerability, and pharmacokinetics."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-023798","json":"https://secwatch.observer/filing/0001493152-24-023798.json","markdown":"https://secwatch.observer/filing/0001493152-24-023798.md","text":"https://secwatch.observer/filing/0001493152-24-023798.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/0001493152-24-023798-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315224023798/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:16:08.393758+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}